Navigation Links
Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Date:8/19/2007

SEATTLE, Aug. 17 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced publication of results from a Phase 1 study of NEUVENGE, an investigational active cellular immunotherapy, in the August 20 issue of the Journal of Clinical Oncology. The article highlights the safety profile, immune response and clinical activity of NEUVENGE in women with HER2/neu-positive breast cancer who have failed standard therapy.

"In addition to demonstrating that NEUVENGE was safe and well tolerated, the T-cell responses seen in these patients and the prolonged disease stabilization in the absence of other anti-cancer therapies in many patients is promising," said John W. Park, M.D., associate clinical professor of medicine and neurosurgery at the University of California, San Francisco and lead author of the publication. "These observations are encouraging and are suggestive of the clinical benefit of NEUVENGE, particularly in light of the aggressive cancer seen in these patients who had progressed while on standard therapy. The findings warrant additional studies of NEUVENGE for the many women with advanced breast cancer who have exhausted many of their treatment options."

Study Design

The Phase 1 study (D2000-2) was conducted to evaluate the safety and immunologic activity of NEUVENGE in patients with HER2-overexpressing metastatic breast cancer who had failed standard therapy, including prior treatment with chemotherapy and trastuzumab. All patients had experienced disease progression while on standard therapy. There were 19 patients enrolled in the study with 18 patients receiving treatment with NEUVENGE. Patients underwent three infusions of NEUVENGE at Weeks 0, 2, and 4 following randomizati
'/>"/>

SOURCE Dendreon Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Presentation of Data at American Urological Association Annual Meeting
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 24, 2014 /PRNewswire/  -- Tianyin Pharmaceutical Inc. (NYSE ... that specializes in the patented biopharmaceutical, modernized traditional ... ingredients (API) released unaudited preliminary financial results for ... Fiscal Year 2015 Ended September 30, 2014 ... compared with $14.7 million in 1Q14 with gross ...
(Date:12/24/2014)... 2014 Soligenix, Inc. (OTCQB: SNGX) (Soligenix ... products that address unmet medical needs in the ... that on December 24, 2014 it closed its ... Company raised approximately $2.3 million in gross proceeds ... net proceeds from the offering to fund its ...
(Date:12/24/2014)... 2014  Conkwest, Inc., the Natural Killer Cell ... Killer (NK) cell-line platform, Neukoplast® (NK-92™) as an ... , NantWorks founder, physician scientist and biotechnology entrepreneur, ... approximately $48 million of the Company,s Class A ... will be named Co-Chairman of the Conkwest Board ...
Breaking Medicine Technology:TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5
... Jan. 10, 2011 Patrick S. Smith, President and Chief ... CURX ), confirmed today that Curaxis is exploring listing ... several weeks as part of a planned multi-city European roadshow ... noted, "Based on our analysis, we believe that listing on ...
... Jan. 10, 2011 Anadys Pharmaceuticals, Inc. (Nasdaq: ... 29th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, ... is being held at Westin St. Francis Hotel in San ... Anadys, will provide an overview of Anadys and its clinical ...
Cached Medicine Technology:Curaxis Pharmaceutical Corp Confirms Exploration of Frankfurt Exchange Listing 2Anadys Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference 2
(Date:12/24/2014)... 2014 The federal court overseeing ... blood thinner caused life-threatening episodes of internal bleeding ... for the proceeding, Bernstein Liebhard LLP reports. According ... plans to select lawyers to serve as Liaison ... appointing a Plaintiffs’ Steering Committee, which will coordinate ...
(Date:12/24/2014)... Mike Billings , PT, MS, CEEAA, ... Fenwick, PT, MBA, GCS, Director of Professional Development to ... passing of the Improving Medicare Post-Acute Care Transformation ... of the Infinicast, the two leaders discuss how the ... Act to standardize post-acute assessment data for quality, payment, ...
(Date:12/24/2014)... Dec. 24, 2014 (HealthDay News) -- Hepatitis C infection does ... to a new study. Treatment advances have made it ... many develop memory and thinking problems, mood swings and other ... said. It,s believed that long-term infections with other viruses ... affect the brain. One of the prime suspects has been ...
(Date:12/24/2014)... Tara Haelle HealthDay Reporter ... Teens are more likely to start smoking or drinking ... disorder (ADHD) or conduct disorder, new research suggests. ... about the risk of substance use as [these] children ... director at Cincinnati Pediatric Research Group, which is part ...
(Date:12/24/2014)... For chic ladies, new fashionable outfits are necessary ... their Holiday Wish List, Angeldress.co.uk has chosen some ... accent ladies’ holiday wardrobe by launching a promotion on its ... the discount of 80% off, like a cheap suit. , ... company’s chic wedding dresses are among the hottest items in ...
Breaking Medicine News(10 mins):Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 3Health News:Latest Episode of Infinicast Features Infinity Rehab President Discussing IMPACT Act of 2014 and Changes for Post-Acute Therapy Providers in 2015 2Health News:Hepatitis C Infection Isn't Related to HIV Brain Woes: Study 2Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 2Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 3Health News:Angeldress.co.uk Starts Its Big Sales by Offering Various Kinds of Cheap Clothes and Fashion Accessories 2
... the Cancer and Leukemia Group B (CALGB) and presented ... assessed the effectiveness of reducing the interval between successive ... survival rates in breast cancer// women. This study was ... developed in the 1980s that suggested the value of ...
... are exposed to smoke, as a reason of having parents ... C levels. Earlier studies have however, revealed the same// results ... 2 to 12 years, who were exposed to smoke at ... lower by an average of 3.2 micromoles per litre than ...
... approved GlaxoSmithKline's new drug Lamictal (lamotrigine) as an addition ... their existing therapy. This new indication is an expansion ... with partial seizures, and for the generalized seizures of ... older. ,Partial seizures are the most common type ...
... has been developed to prevent mix-ups over identification of ... newborns as barcodes, has been introduced in the maternity ... ,As soon as babies are born, their fingerprints, and ... which mother and baby wear on their wrists. The ...
... is bad for health is almost an established truth now. ... damage a single serving of pizza could do to our ... group, called the Centre //for Science in the Public Interest ... 15 varieties of pizzas and looked at dietary information provided ...
... often been connected to gaining excess weight. It has ... be related to the hormone leptin, which regulates appetite ... that leptin levels were high during smoking periods, thus ... leptin levels plummet leading to weight gain. ,A ...
Cached Medicine News:Health News:Survival rates in breast cancer patients improved with "Dose Dense Chemotherapy" 2Health News:Pizza is bad for health. But, do you know how bad? 2
The HT-PB is a implantable bipolar tined permanent pacing lead for stimulation of the ventricle....
The Guidant Fineline leads are bipolar endocardial and designed for permanent implantation with pulse generators for cardiac pacing....
Steroid-eluting, screw-in pacing lead...
... The Guidant Flextend ... transvenous pace/sense lead with ... The extendable/retractable helix design ... possibilities for permanent implantation ...
Medicine Products: